Edwards Lifesciences (NYSE:EW) Sets New 52-Week High – Here’s What Happened

Shares of Edwards Lifesciences Corporation (NYSE:EW) reached a new 52-week high during trading on Monday . The company traded as high as $94.60 and last traded at $93.1050, with a volume of 222940 shares. The stock had previously closed at $94.37.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $96.39.

Edwards Lifesciences Stock Down 0.7%

The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average price of $85.61 and a two-hundred day moving average price of $83.57. The company has a market capitalization of $53.94 billion, a price-to-earnings ratio of 49.82, a P/E/G ratio of 2.37 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 57,958 shares of company stock worth $4,839,284. 0.31% of the stock is currently owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the business. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences during the first quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences in the fourth quarter worth about $27,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.